Global Information
회사소개 | 문의 | 비교리스트

방사선 독성(방사선증, 급성 방사선 증후군) : 파이프라인 리뷰

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 229758
페이지 정보 영문 278 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


방사선 독성(방사선증, 급성 방사선 증후군) : 파이프라인 리뷰 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 278 Pages

방사선 독성(방사선증, 급성 방사선 증후군)은 매우 짧은 시간 동안(보통 몇 분 안에) 고선량의 방사선을 전신(또는 거의 전신)에 투과함으로써 발생하는 급성 질환입니다. 코, 입, 잇몸에서의 출혈, 혈변, 타박상, 정신혼란, 탈수, 설사, 실신, 피로 등의 증상이 나타납니다.

방사선 독성(방사선증, 급성 방사선 증후군) 치료제의 개발 상황에 대해 조사 분석하고, 파이프라인 제품 개요, 임상 단계별 제품 개요, 주요 기업 개요, 치료제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

방사선 독성(방사선증, 급성 방사선 증후군) 개요

치료제 개발

  • 파이프라인 제품 개요
  • 파이프라인 제품 비교 분석

방사선 독성(방사선증, 급성 방사선 증후군) : 기업에서 개발중인 치료제

방사선 독성(방사선증, 급성 방사선 증후군) : 대학/기관에서 연구중인 치료제

방사선 독성(방사선증, 급성 방사선 증후군) : 파이프라인 제품 상황 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품
  • 개발 단계가 불명확한 제품

방사선 독성(방사선증, 급성 방사선 증후군) : 기업에서 개발중인 제품

방사선 독성(방사선증, 급성 방사선 증후군) : 대학/기관에서 연구중인 제품

방사선 독성(방사선증, 급성 방사선 증후군) 치료제 개발에 참여하고 있는 기업

  • Aeolus Pharmaceuticals, Inc.
  • Angion Biomedica Corp.
  • Atox Bio Inc.
  • Avaxia Biologics, Inc.
  • Bolder Biotechnology, Inc.
  • Caladrius Biosciences, Inc.
  • Cellerant Therapeutics, Inc.
  • Cellphire, Inc.
  • Chrysalis BioTherapeutics, Inc.
  • Cleveland BioLabs, Inc.
  • Cumberland Pharmaceuticals, Inc.
  • Diffusion Pharmaceuticals Inc.
  • Eli Lilly and Company
  • GNI Group Ltd.
  • Humanetics Corporation
  • INSYS Therapeutics, Inc.
  • Meabco A/S
  • Neumedicines Inc.
  • Onconova Therapeutics, Inc.
  • PharmaIN Corporation
  • Pluristem Therapeutics Inc.
  • ProCertus BioPharm Inc.
  • RDD Pharma Ltd.
  • RedHill Biopharma Ltd.
  • RxBio, Inc.
  • Soligenix, Inc.
  • Stemedica Cell Technologies, Inc.
  • Terapio Corporation
  • Tonix Pharmaceuticals Holding Corp.

방사선 독성(방사선증, 급성 방사선 증후군) : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

약제 프로파일

방사선 독성(방사선증, 급성 방사선 증후군) : 최근의 파이프라인 동향

방사선 독성(방사선증, 급성 방사선 증후군) : 휴지 상태인 프로젝트

방사선 독성(방사선증, 급성 방사선 증후군) : 개발이 중지된 제품

방사선 독성(방사선증, 급성 방사선 증후군) : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

LSH 16.10.07

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by 21st Century Therapeutics Inc, H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Advanced Innovative Partners Inc, H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Advenchen Laboratories LLC, H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Amryt Pharma Plc, H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Angion Biomedica Corp, H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Atox Bio Ltd, H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by BCN Biosciences LLC, H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2020 (Contd..4), H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Toxicity - Pipeline Review, H1 2020, provides an overview of the Radiation Toxicity (Toxicology) pipeline landscape.

Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Symptoms include bleeding from the nose, mouth, gums, and rectum, bloody stool, bruising, confusion, dehydration, diarrhea, fainting and fatigue.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Radiation Toxicity - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Radiation Toxicity (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiation Toxicity (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 7, 8, 1, 44, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively.

Radiation Toxicity (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Radiation Toxicity (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Radiation Toxicity (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Radiation Toxicity (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Toxicity (Toxicology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Radiation Toxicity (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Radiation Toxicity (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Development
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drug Profiles
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q